PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named Health Union as one of the most innovative Companies of 2018.
The impact of cancer can have negative effects on finances, but not many patients even consider cost to be a factor in making their treatment decisions.
Health Union was recognized today as the No. 1 company in the Medium Agency category in Medical Marketing & Media’s (MM&M) inaugural Best Places to Work Class of 2018.
Health Union ranked No. 162 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies — both public and private — in North America.
Health Union has been accepted for a poster presentation to assess the online health community model with qualitative data.
Survey results from Bladder Cancer In America 2018, Health Union LLC’s national survey of 401 respondents conducted among both patients and care partners impacted by the condition, show that for people in remission, a number of factors beyond the treatment itself contributed to reporting good experiences with bladder cancer.
Results from Endometriosis In America 2018, a national survey by Health Union, LLC of people impacted by the condition, contribute to the notion that an early diagnosis after initial symptoms are experienced can help to improve quality of life and provide greater awareness of symptoms.
Inc. magazine announced that Health Union has been ranked No. 740 on the 37th annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. After steadily receiving awards and recognitions within the Philadelphia business community and life sciences industry over the past eight years, the Inc. 5000 represents Health Union’s first national recognition.
People living with migraine recently gained another significant tool to effectively manage their condition when the U.S. Food and Drug Administration approved the first treatment to target calcitonin-gene-related peptides (CGRP). However, only one-third of respondents of Migraine In America 2018, a national survey by Health Union, LLC of people impacted by the condition, are even aware of CGRP therapies.
Living with lung cancer is accompanied by a considerable level of anxiety, with 86 percent of respondents reporting at least a little bit of anxiety on any given day. However, what is often referred to as “scanxiety” – the anxiety, fear and worry associated with scans, specifically before the results are revealed – can exacerbate those feelings. Of those who experience scanxiety, three-quarters reported either “more” or “a lot more” anxiety around the time of scans than at other times.
1218 Chestnut St., 3rd Floor
Philadelphia, PA 19107
Phone: 484-985-9715
Fax: 484-450-2513
Privacy Notice
Terms of Use
Your Privacy Choices 
Privacy Rights Request Form
Join Our Team
Press Kit